in this issue
Regions :: Western Europe :: Italy
Cambrex Gets FDA Warning on Milan API Facility
10:25 PM MDT | August 24, 2009 | Deepti Ramesh
Cambrex (East Rutherford, NJ) says it has received a warning letter from the U.S. FDA, relating to the collection and maintenance of certain laboratory data at the company’s generic active pharmaceutical ingredients (API) manufacturing facility at Milan, Italy. The warning letter follows an FDA inspection of the Milan facility in March 2009. The warning letter indicated that until Cambrex corrects all the observations, the FDA may withhold approval of new applications or supplements listing the Milan facility as the API manufacturer, and products...
This information is only available to Chemical Week subscribers.
Forgot your user ID or password?
Not an IHS Chemical Week member yet?
Here's why you should be:
100% Satisfaction Guarantee